11
Drug conjugates
Antibody Drug Conjugates (ADCs) deliver a
small molecule drug to a very specific target in
the cells. Researchers developing ADCs need
to understand how covalent attachment of a
small molecule drug affects the overall stability
and behavior of their antibody. The conjugation
process can destabilize it; furthermore, once that
it's carrying the drug, its long term formulation
and storage can be affected. DLS allows
researchers to monitor how conjugation impacts
their antibody stability.
Bispecifics
The latest trend in building better biologics is
developing bi- or multi- specific Abs and Ab-
derived molecules that act as targeted carriers
of a drug or treatment. These biologics are
usually derived from the variable chains of the
Fab region of the antibody, and they target
both the payload that they carry and the cell-
specific receptor they are delivering to. DLS not
only informs how these engineered fragments
behave long term, but also help researchers
determine whether or not the drug or target is
binding the bispecific.
